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Objectives. To evaluate the safety and effectiveness of the injectable bulking agent Opsys (Promedon, Cordoba, Argentina) for
treating minimal postprostatectomy stress urinary incontinence (SUI). Patients and Methods. Single-centre, pilot study on ten
male patients with SUI, < 30 g urine loss/ 24 h, more than 1 year after radical prostatectomy. Patients were treated by endoscopic
transurethral injections of bulking agent in the presphincteric zone of the urethral submucosa. The results were evaluated using a
pad weight test to quantify the differences in urine loss at 1, 3, and 6months after intervention. Subsequently, the results of treatment
were also evaluated by International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF), Incontinence Impact
Questionnaire (IIQ-7), Urogenital Distress Inventory Short Form (UDI-6-SF), and the Patient Global Impression of Improvement
(PGI-I) at 1, 3, and 6months after intervention.Results.The primary outcome was the absolute result of the 24-hour pad weight test
after treatment. Treatment success was defined as <3 g urine loss/24 h, improvement as ≥50% decrease in urine loss/ 24h, failure as
<50% decrease in urine loss/24 h, or worsening of urine loss. Success was demonstrated in one, improvement in one, and failure in
eight patients one month after treatment. One patient improved and 9 failed 3 and 6 months after treatment. The median 24-hour
pad weight test was higher at all three moments of follow-up (1, 3, and 6 months after treatment).The median 24-hour pad weight
test was before treatment 17.3g (6.4-20.9) and 1, 3, and 6months after treatment, respectively, 40.3g (5.9-130.6) p= 0.038, 38.3g (18.3-
202.1) p= 0.014, 55.0g (16.5-314.6) p= 0.028. The ICIQ-SF was significantly higher at 3 and 6 months, respectively 15.0 (12.0-18.5)
p= 0.007 and 16.0 (12.5-17.5) p=0.012 versus 10.0 (9.0-12.0) before injection. No significant differences were found between IIQ-
7, UDI-6-SF, and PGI-I before and after injection. Complications occurred in four patients: two patients reported spontaneously
resolved haematuria and two patients reported urinary frequency. All complications were classified asClavien–Dindo 1.Conclusion.
Injection therapy with Opsys bulking agent is not an effective treatment option for male SUI after radical prostatectomy. It is not
a safe treatment option, due to worsening urine loss after treatment.
1. Introduction
Urinary incontinence after radical prostatectomy has a high
impact on patients’ quality of life. The current guidelines on
postprostatectomy urinary incontinence stated that surgical
treatments can be considered for men who fail conserva-
tive treatment [1]. The artificial urinary sphincter is still
considered the gold standard for treating postprostatectomy
incontinence [2]. The male sling and Proact balloons, how-
ever, have proved to be good alternative treatment options
for patients with mild postprostatectomy incontinence [3].
However, there is still no appropriate minimal invasive
intervention available for minimal postprostatectomy incon-
tinence (<30 g urine loss/24-hour pad test), though injection
of a bulking agent might be a solution. Multiple bulking
agents have been used for treatment of female stress urinary
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incontinence (SUI) with inconsistent results on effectiveness
[4]. The Opsys (Promedon, Cordoba, Argentina) bulking
agent seemed to be safe and effective for treating female
SUI and can be offered as a minimally invasive procedure
with quite durable clinical results andminimal complications
[5]. Opsys is made of a polyacrylate polyalcohol copolymer,
and it is a nonabsorbable biomaterial which is also used in
children to treat vesicoureteral reflux [6]. The biocompati-
bility and nonmigration characteristics as well as long term
bulking stability in the injection site of Opsys have been
studied in in-vivo and in-vitro studies [7]. Various kind of
bulking agents have been used to treat male incontinence,
the outcome was variable, and the reintervention rate of
52.9% was high [8]. However, there are no scientific data
regarding the efficacy and safety of Opsys for treating
postprostatectomy incontinence [8]. We hypothesised that
injection of the bulking agentOpsysmight be an appropriate
minimal invasive treatment for patients with minimal SUI
after prostatectomy. The expectation was that bulking agents
could replace the more invasive and more comorbidity-
related implantation of slings and Proact balloons for these
patients.We present a pilot study that evaluated the safety and
efficacy of the injectable bulking agent Opsys for treating
postprostatectomy SUI.
2. Materials and Methods
2.1. Inclusion and Exclusion Criteria. All patients gave their
written informed consent before inclusion in the study.
The study was approved by the local ethics committee
and registered in the Dutch Trial registration as number
NL.57054.044.15. Patients were included in this pilot study
and treated with Opsys bulking agent between October and
December 2016. Inclusion criteria were minimal SUI (<30
g/day loss during the 24-hour pad weight test), at least 12
months after radical prostatectomy, and being refractory to
conservative treatment, such as pelvic floor muscle training.
Patients remained dry at night and could voluntarily stop
micturition. Patients with a history of radiation treatment for
prostate carcinoma, bladder neck sclerosis, urethral stricture,
urgency urinary incontinence, detrusor overactivity during
urodynamic evaluation, and/or urinary tract infection were
excluded from the study.
2.2. Bulking Agent. Opsys consists of particles of poly-
acrylate polyalcohol copolymer which is a nonabsorbable
biomaterial. It has a very high molecular mass (∼10,000 kDa)
and comes in the form of sterile pyrogen-free particles. The
macroparticles have an average diameter of 300 𝜇m and the
carrier is a 40% glycerol solution. This substance can be
manually injected easily through small needles (21-gauge).
Once implanted, the glycerol solution is eliminated by the
reticuloendothelial system without metabolizing it and is
excreted through the kidneys, leaving the particles behind for
permanent bulking [7].
2.3. Injection Procedure. Broad-spectrum antibiotics were
administered. General or regional anaesthesia was given
based on patients' preference. All procedures were performed
in the operating room. Opsys was implanted using a video
endoscope with 6-French working channel, 0∘ optics, and
a 21-gauge transurethral injection needle. All procedures
were video-recorded. The bulking agent was injected in
a transurethral manner into the presphincter zone of the
urethral submucosa. Injections of about 1.0 mL of bulking
agent around all quadrants in the urethra were executed.
The bladder was emptied after the procedure by a single use
catheter 12 French.
2.4. Follow-Up. All patients were assessed prior to treat-
ment via their medical history, physical examination, and
endoscopic- and urodynamic evaluations including postvoid
residual volume. All patients were assessed again 1, 3, and
6 months after treatment. Pretreatment and posttreatment
SUI were evaluated using two 24-hour pad weight tests.
Posttreatment success was defined as a maximum of 3 g of
urine loss during the 24-hour pad weight test. Improvement
was defined as a ≥50% reduction of urine loss during the 24-
hour pad weight test. Failure was classified as<50% reduction
or increased urine loss during the 24-hour pad weight test.
Uroflowmetry and postvoid residual volume was mea-
sured each post treatment visit.
The following validated questionnaires were adminis-
tered preoperatively and at every follow-up visit: Interna-
tional Consultation on Incontinence Questionnaire Short
Form (ICIQSF), Incontinence Impact Questionnaire (IIQ-7),
and Urogenital Distress Inventory Short Form (UDI-6-SF).
In addition, the Patient Global Impression of Improvement
(PGI-I) was assessed postoperatively [1]. Complications were
assessed and classified using the Clavien–Dindo classification
[9].
2.5. Statistical Analysis
2.5.1. Power Calculation. A total of 30 subjects were planned
to be included in this clinical study, distributed among two
research centres.The inclusion of 30 patients within the given
time period was feasible for the two centres. Injection of
Opsys was expected to result in a success percentage of
30-50%. The sample size calculation was based on the two-
sided confidence interval formula (Score (Wilson)) for one
proportion. This was calculated using PASS 11. A sample size
of 30 produces a two-sided 95% confidence interval with a
width equal to 0.337 when the sample proportion is 0.500:
0.332 to 0.668.
2.5.2. Follow-Up Data. Continuous normally distributed
variables are reported as means with standard deviation
(SD), and continuous nonnormally distributed variables are
presented as medians with interquartile range (IQR). The
preoperative and postoperative (1, 3, and 6 months) 24-
hour pad weight test ICIQ-SF, IIQ-7, UDI-6-SF, and PGI-I
scores were compared using the Wilcoxon signed-rank test.
To analyse the PGI-I score at 1, 3, and 6 months, we adapted
a baseline value of 4.0, which indicated no change.
A p-value <0.05 was considered to be statistically signifi-
cant. All data were analysed using SPSS version 23.0.
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Table 1: Baseline characteristics.
Variable N=10
Age (years), mean ± SD 67.0 ± 6.1
BMI (kg/m2), mean ± SD 29.7 ± 6.3
Mode of previous prostate surgery, n (%)
Open radical prostatectomy 5 (50)
Robot-assisted radical prostatectomy 4 (40)
Laparoscopic radical prostatectomy 1 (10)
Anaesthesia, n (%)
Spinal 5 (50)
General 5 (50)
Operation time (min), mean ± SD 14.1 ± 3.8
Number of injections, mean ± SD 4.7 ± 1.1
Total injected volume (mL), mean ± SD 2.3 ± 1.5
3. Results
Ten patients were included in the pilot study. The calculated
power of 30 patient was not accomplished due to an inclusion
stop after interim analysis of the effectiveness and safety
results of the first 10 patients. Table 1 summarizes the baseline
characteristics. The mean patient age was 67.0 years (range
55–77 years). The mean BMI was 29.7 kg/m2 (range 21-44
kg/m2). The following comorbidities were present: hyper-
tension (n=4), diabetes mellitus (n=3), hypercholesterolemia
(n=2), sleep apnoea syndrome (n=1), and chronic obstructive
pulmonary disease (n=1). Three patients did not have signif-
icant comorbidities. The postvoid residual volume was in all
patients < 50 mL.
The mean number of transurethral injections per patient
was 4.7 (range 3–7). The mean total injected volume of
bulking agent was 2.3 mL (0.3–5.0 mL).
Complications occurred in four patients. Two patients
had light haematuria for 2–4 days after the injection that
resolved by itself. Two patients reported urinary frequency,
one patient for 1 day after the injection and one patient for 2
months. All complications were classified as Clavien–Dindo
1.
The results after 1month showed one patient with success,
one with improvement, and eight with failure (Table 2). At
3 and 6 months’ follow-up, none of the patients showed
a successful outcome: one patient exhibited improvement
and nine patients showed failure. The median 24-hour pad
weight test was significantly higher 1, 3, and 6 months after
injection of the bulking agent, respectively, 40.3 g (5.9-130.6)
p= 0.038, and 38.3 g (18.3-202.1) p= 0.014, 55.0 g (16.5-
314.6) p= 0.028, compared with baseline, 17.3 g (6.4-20.9).
Posttreatment clinical examination/interview demonstrated
no signs of urge incontinence. Posttreatment residual volume
was in all patients below 50 mL.
The ICIQ-SF was significantly higher after 3 months,
15.0 (12.0-18.5) p= 0.007, and 6 months, 16.0 (12.5-17.5)
p=0.012, compared with baseline, 10.0 (9.0-12.0) (Table 2). No
significant differences were found between the IIQ-7, UDI-6-
SF, and PGI-I scores before and after injection.
4. Discussion
SUI greatly affects patients’ quality of life. The minimally
invasive procedure that entails injecting the bulking agent
Opsys in patients who have minimal SUI failed in 9 of the
10 patients. Consequently, the inclusion of patients in the
study was stopped before the calculated power of 30 patients
was reached. Furthermore, the follow-up in the study was
shortened by 6 months instead of 12 months in the initial
protocol. So, patients were able to get another treatment
for incontinence. Subsequently, one patient was treated with
an artificial urinary sphincter and two patients with a male
sling. All three patients were dry after this reintervention.
The remaining 6 patients who did not improve after injection
treatment refused an additional treatment. Amajor weakness
of this study is the small sample size and the lack of an
appropriate control group. However, it is also important to
publish these results and to suggest explanations for the poor
outcome of the injection of the bulking agent Opsys.
First, three independent urologists expert inmale urinary
incontinence evaluated the recorded videos of the endoscopic
injection procedures of the patients. They provided a blinded
prediction of the functional outcome of each injection proce-
dure. There was no correlation between any of the predicted
results and the real-time outcomes. The experts concluded
that all injection procedures were performed according to
the technical description in the protocol. The independent
urologist checked for the following eight steps of injection
procedures: (1)The endoscope was introduced in the bladder
and the injection needle in the endoscope till the tip of the
needle was seen; (2) the endoscope and the tip of the needle
removed backward up to the presphincter zone; (3) the needle
was injected at a 30∘-45∘ angle with regard to the urethral
mucosa; (4) the endoscope was placed at a 0∘ angle, parallel
to the urethra; (5) the position of the needle was checked
injecting a small amount of product, which demonstrated
bulkiness in the urethral submucosa and around 1mLOpsys
was injected; (6) the needle was removed from the injection
site after 15-30 seconds; (7) the clinician injected at four
quadrants in the urethral submucosa or till bulkiness and
closing of the urethral lumenwas observed; (8) the endoscope
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Table 2: Postoperative results. P-values correspond to the Wilcoxon signed-rank test for comparing baseline with 1, 3 and 6 months follow-
up. ICIQ-SF = International Consultation on Incontinence Short Form; IIQ-7 = Incontinence Impact Questionnaire; UDI-6-SF = Urogenital
Distress Inventory Short Form; PGI-I = Patient Global Impression of Improvement. ∗∗ n.c. = no change; for statistical analysis we adopted a
baseline value of 4.
Baseline 1 month P 3 months P 6 months P
(n=10) (n=10) (n=10)
Treatment outcome, n (%)
Success 1 (10) 0 (0) 0 (0)
Improvement 1 (10) 1 (10) 1 (10)
Failure 8 (80) 9 (90) 9 (90)
24-h pad weight test (g), median (IQR) 17.3 (6.4 – 20.9) 40.3 (5.9 – 130.6) 0.038 38.3 (18.3 – 202.1) 0.014 55.0 (16.5 – 314.6) 0.028
ICIQ-SF score, median (IQR) 10.0 (9.0 – 12.0) 16.0 (11.8 – 18.0) 0.109 15.0 (12.0 -18.5) 0.007 16.0 (12.5 – 17.5) 0.012
IIQ-7 score, median (IQR) 26.5 (13.0 – 41.5) 38.0 (34.5 – 50.3) 0.122 49.5 (17.8 – 67.0) 0.413 36.0 (15.5 – 62.0) 0.528
UDI-6-SF score, median (IQR) 33.0 (20.8 – 40.3) 36.0 (26.5 – 44.0) 0.553 39.0 (17.0 – 58.5) 0.552 39.0 (28.0 – 47.0) 0.766
PGI-I score, median (IQR) n.c.∗∗ 5.5 (4.8 – 6.0) 0.102 4.5 (3.8 – 6.0) 0.121 5.0 (3.5 – 5.0) 0.206
was not moved forward through the injection site, since this
could deform injected material bulkiness.
Second, we used magnetic resonance imaging (MRI) of
the pelvis/urethra to evaluate the anatomical positioning of
the bulking agent after injection. Postinjection MRI was not
part of the protocol. However, we performed postinjection
MRI in all patients to investigate the poor outcome after
injection. A radiologist of the study centre and two authors
of this manuscript assessed the MRI results. It showed no
correlation between the demonstrated MRI bulking agent
around the urethra and the number of injections, volume
of the injections, location of injections, or functional out-
come (Figure 1). The differences between location/volume
of injection and the MRI results are difficult to explain.
There should be no risk of migration around the injection
site or to other parts of the body because of the 300 𝜇m
average diameter of the polyacrylate polyalcohol copolymer
particles. Because these macroparticles are flexible, irregu-
larly shaped, and highly deformable by compression, they
may be extruded using 21-gauge needles. Once implanted,
macroparticles enlarge the volume of the tissue, generating
little fibrotic growth around them (i.e., 70–125 𝜇m thick)
[7]. Subsequently, MRI evaluation of the injection technique
and the anatomical position of the bulking agent did not
result in an explanation of failure or even worsening of the
urinary incontinence. The results of our study were therefore
disappointing compared with the former results of Opsys in
women with SUI [5]. Hence, we must address the causes of
the failed treatment of male SUI after radical prostatectomy.
Figures 1(a) and 1(b) MRI views demonstrated different
location and amount of bulking agent on 3.5 mm slides. Both
patients had 5 injections with bulking agent. The urethra can
be recognized by the transurethral catheter.
Postprostatectomy urinary incontinence is due to damage
of the anatomic support and pelvic innervation.The anatomic
support consists of the urethral sphincter complex for passive
and active continence and the anterior and posterior support
structures around the urethra and the pelvic floor [10].
Women also have internal sphincter deficiency, but the
aetiology of urinary incontinence is different between the
sexes. In men, pelvic surgery leading to neurovascular and
anatomic support damage is the main cause, while birth-
related trauma is the main cause in women. The trauma
that induces urinary incontinence in men tends to occur at
an older age (sixties onwards) than in women (childbearing
age). The collagen tissue surrounding the urethra might
be less supportive in older patients, especially if there is
neurovascular damage.The bulking agent around the urethra
might have further diminished the vascularisation of the
urethra due to obstruction by the bulk material. Our results
compare unfavourably to earlier results with Opsys in the
treatment of female SUI and other published results on
bulking agents in the treatment of male SUI. One patient
showed increased incontinence (>1000mL / 24 hours) and
was additionally treated by an artificial urinary sphincter
implant. To our knowledge, this worsening of incontinence
after bulking agent injection was never published. The for-
mer published studies on transurethral injection of collagen
demonstrated a short-term success rate of 44–58%. None
of those studies, however, were randomised or placebo-
controlled. A subsequent review published in 1996 concluded
that transurethral injection with collagen has a limited role
in the management of urinary incontinence [11]. Macroplas-
tique injections demonstrated a success rate of 43% and even
dry rates up to 80% in a selected group of patients with
minimal incontinence [12, 13]. Chughtai et al. evaluated all
interventions for SUI or mixed incontinence in male patients
during 2000–2011 [8]. This study showed that the use of
bulking agent has decreased from 52.2% to 16.4% in favour
of sling surgery, which increased from 14.8% to 51.4%. One
of the reasons for this might be the higher reintervention rate
during the first year following surgery in patients treated with
bulking agents (40.1%) comparedwith the sling (9.7%) and an
artificial urinary sphincter (7.1%). Our hypothesis regarding
the failure of Opsys bulk injection in the present study is that
postprostatectomy urinary incontinence has multifactorial
causes, including anatomic support and pelvic innervation
damage. These multifactorial causes are not resolved by
injecting this bulking agent.
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(a) Patient with 5 submucosal urethral injections at 1, 3, 5, 7, and 9 o’clock, total amount of Opsys injected
is 2.5 mL. Two transverse views. Lateral and dorsal of the urethra are white spots which shows bulking agent
(b) Patient with 5 submucosal urethral injections at 2,
5, 6, 8, and 10 o’clock, total amount of Opsys injected
is 4.0mL. Only 1 transverse view onMRI shows awhite
spot which shows the bulking agent
Figure 1:Magnetic resonance imaging (MRI∗) views of bulking agent.∗1.5 T SiemensAvantoMRI:T2 Blade 3,5mm sagittal, T1 space coronal
0.9mm, T2TSE transversal 3.5mm, T2TSE coronal oblique 3.5mm, andT2TSE coronal 3.5mm. Technical aspects: FieldOfView 240mm, distance
30%, phase right to left, resolution 320, and phase resolution 86%.
5. Conclusions
Injection of Opsys bulking agent is not a safe and effective
treatment option for male SUI after radical prostatectomy.
The treatment resulted in worsening of the minimal SUI. We
could not find an evident explanation for these results. So, we
could not suggest adaptions to improve the treatment with
Opsys bulking agent in male SUI.
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